With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. 2
Pharmaceuticals

With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. 2

Staff Reporter 2914 Views 0 Comments

In developing a treatment for Clostridium difficile—an infection that can cause life-threatening diarrhea—Ferring Pharmaceuticals has had to dig deep in a decadelong pursuit, experimenting with bac | The FDA has signed off on Ferring Pharmaceuticals’ Rebyota, a one-time, enema-delivered therapy for Clostridium difficile that can restore proper bacterial balance in the digestive system. As the first FDA-approved fecal microbiotica product, Rebyota represents a significant milestone, potentially clearing the way for other such treatments.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source

Leave a Reply